Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Interleukin 1alpha rs1800587 associates with chronic non-crisis pain in sickle cell disease
source: The Journal of Pain
year: 2016
authors: X. Hu, E. Jhun, Y. Yao, Y. He, R. Molokie, D. Wilkie, Z. Wang
summary/abstract:Pain is prevalent in sickle cell disease (SCD) patients who display great heterogeneity in pain severity and frequency. Studying the contribution of relevant candidate gene polymorphisms may shed light on the etiology of the pain heterogeneity, allowing for precision pain medicine in SCD. We hypothesize that inflammatory factors are involved in the pathogenesis of sickle cell pain. In this study, we focused on the IL1A C/T polymorphism rs1800587 that is a single nucleotide polymorphism (SNP) located at position -889. The SNP came to our attention because our bioinformatic analysis predicted that this SNP is located in a cis-transcriptional regulatory region modulating the protein expression level. Pain phenotype data were gathered from PAINReportIt, a pain assessment tool for multidimensional pain experience. The composite pain index (CPI) was used as a measurement for the baseline pain. Utilization of urgent or emergency care due to sickling pain crisis was used as a surrogate for acute pain crisis in SCD. We found the T allele was associated with increased CPI. In our SCD cohort, each T allele was associated with a 3.9 increase in CPI (p=0.04), accounting for 3% of variability in CPI as determined by the additive multiple linear regression. We did not find significant association between this SNP and the patient utilization due to acute pain. These results represent the first indication that IL1A rs1800587 may influence the chronic non-crisis pain in SCD.
organization: Department of Biopharmaceutical Sciences and Sickle Cell Center, University of Illinois, ChicagoDOI: 10.1016/j.jpain.2016.01.186
read more
Related Content
-
Could Gene Therapy Cure Sickle Cell Anemia?Nearly 20 years ago, scientists stunned ...
-
Outcomes of an Emergency Department Observation Unit–Based Pathway for the Treatment of Uncomplicated Vaso-Occlusi...Study objective: This was a prospective...
-
Development of a multi-center cohort to evaluate long-term outcomes and late effects following hematopoietic cell tr...Hematopoietic cell transplantation (HCT)...
-
SUSTAIN Clinical Trial Results Show Crizanlizumab Reduced Sickle Cell–Related Pain CrisesResults from the Phase 2 SUSTAIN clinica...
-
Children’s Hospital of MichiganThe Sickle Cell Center at the Children's...
-
Emmaus Life Sciences, Inc. to present results of phase 3 study of endariTM (L-glutamine oral powder) at 59th America...Emmaus will present results of a Phase 3...
-
Warren rapper draws influence from sickle cell diagnosisSeventeen-year-old Ja’Vionte “Tae Mo...
Don’t forget to join the oneSCDvoice community!
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Don’t forget to join the oneSCDvoice community!
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.